Johnson & Johnson Stock Price, News & Analysis

A Boston jury has awarded $42.6 million to Paul and Kathryn Lovell in a landmark lawsuit against Johnson & Johnson (NYSE:JNJ), marking the largest mesothelioma verdict in Massachusetts history. The case centered on Mr. Lovell's mesothelioma diagnosis, which was linked to asbestos contamination in J&J's baby powder products.

During the two-week trial, attorneys from Dean Omar Branham Shirley presented evidence showing J&J had knowingly concealed health risks associated with their talc products for decades. Internal documents revealed the company's awareness of asbestos contamination, failure to adopt safer alternatives, and manipulation of scientific testing methods. The jury found J&J guilty of negligence and breach of warranty.

Johnson & Johnson (NYSE:JNJ) has launched the VIRTUGUIDE™ System, an AI-powered solution for bunion surgery that received FDA 510(k) clearance earlier this year. The system, designed for Lapidus procedures, uses pre-operative planning software developed with PeekMed® to create personalized surgical recommendations.

Early adopters report 30-minute reductions in surgical time compared to traditional techniques. The technology addresses a significant medical need, as bunions affect approximately one-third of U.S. adults. The VIRTUGUIDE™ System joins J&J's VELYS™ Enabling Tech solutions portfolio, aiming to streamline surgical procedures and improve accuracy through patient-matched instrumentation.

Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application (sBLA) to the FDA for TREMFYA® (guselkumab) seeking to include new evidence of joint structural damage inhibition in active psoriatic arthritis (PsA) patients.

The submission is supported by the Phase 3b APEX study, which achieved its primary endpoint of reducing joint symptoms (ACR20) and secondary endpoint of inhibiting structural damage progression at 24 weeks. TREMFYA® would become the first and only IL-23 inhibitor proven to both control symptoms and significantly inhibit joint damage progression in active PsA.

As a dual-acting monoclonal antibody, TREMFYA® uniquely blocks IL-23 while binding to CD64, demonstrating a well-established safety profile in the study.

Johnson & Johnson (NYSE: JNJ) announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. The company's management will engage in a Fireside Chat on September 3rd, 2025, at 11:50 a.m. Eastern Time.

Investors can access the live audio webcast through JNJ's Investor Relations website. An archived version will be available approximately 48 hours after the presentation.

Johnson & Johnson (NYSE:JNJ) will present significant advancements in Alzheimer's disease research at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto. The company will showcase 12 research abstracts focusing on tau's impact on brain function in early Alzheimer's and the predictive capabilities of plasma biomarker pTau217.

A key highlight includes new findings from the Global Neurodegeneration Proteomics Consortium (GNPC), a partnership between J&J and Gates Ventures, representing the world's largest neurodegenerative disease proteomics resource. The research spans various areas, including tau PET imaging, CSF proteomics, plasma biomarkers, and AI-based diagnostic approaches.

Johnson & Johnson (NYSE:JNJ) has submitted a New Drug Application (NDA) to the FDA for icotrokinra, a first-in-class targeted oral peptide for treating moderate to severe plaque psoriasis in adults and patients 12+ years old. The submission includes data from four Phase 3 studies (ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 & 2) where icotrokinra met all primary endpoints.

The drug demonstrated superior efficacy to deucravacitinib and showed promising results in difficult-to-treat areas. Safety data revealed similar adverse events between icotrokinra (49.1%) and placebo (51.9%). The company has also initiated ICONIC-ASCEND, the first head-to-head study comparing an oral pill (icotrokinra) to an injectable biologic (ustekinumab).

Johnson & Johnson (NYSE: JNJ) announced that the FDA has granted Priority Review for TAR-200, an innovative intravesical drug releasing system for treating high-risk non-muscle invasive bladder cancer (HR-NMIBC) in patients who are unresponsive to BCG therapy.

The Phase 2b SunRISe-1 study demonstrated impressive results with an 82.4% complete response rate, and 52.9% of patients remaining cancer-free for at least one year. TAR-200 represents the first significant innovation in bladder cancer drug delivery in over 40 years, providing sustained local treatment delivery over three weeks per cycle.

The treatment can be administered in an outpatient setting in under five minutes, requiring no general anesthesia or additional monitoring.

Dean Omar Branham Shirley trial attorney Aaron Chapman has been recognized in the 2025 Lawdragon 500 X – The Next Generation legal guide for his work in plaintiff litigation. Chapman was part of a trial team that secured an $8 million verdict against Johnson & Johnson (NYSE: JNJ) in Suffolk County, Mass., representing a woman who developed mesothelioma from talcum powder products.

The attorney has notable experience in asbestos litigation across multiple states and previously helped secure the largest asbestos-related personal injury verdict in Nevada in 2021. The recognition by Lawdragon highlights emerging legal leaders selected through nominations, research, and peer recommendations.

Johnson & Johnson (NYSE: JNJ) has announced its quarterly dividend for Q3 2025. The company's Board of Directors has declared a cash dividend of $1.30 per share on its common stock. The dividend will be paid on September 9, 2025 to shareholders of record as of August 26, 2025, which is also the ex-dividend date.